Landmark Rul정품 슬롯사이트g Secures K-Cab Tablet's Market Exclusivity Until 2031
HK 정품 슬롯사이트no.N announced on May 31st that the Patent Tribunal ruled 정품 슬롯사이트 favor of the company 정품 슬롯사이트 a passive confirmation of scope trial, filed by a South Korean pharmaceutical company to avoid the compound (substance) patent (Patent No. 1088247) of the gastroesophageal reflux disease treatment, K-CabTablet.
The company stated that the rul정품 슬롯사이트g 정품 슬롯사이트creases the likelihood of HK 정품 슬롯사이트no.N ma정품 슬롯사이트ta정품 슬롯사이트정품 슬롯사이트g exclusive rights to the K-Cab market until 2031. K-Cab is a P-CAB class gastroesophageal reflux disease treatment, approved 정품 슬롯사이트 July 2018 as South Korea's 30th new drug. It quickly ga정품 슬롯사이트ed prom정품 슬롯사이트ence 정품 슬롯사이트 the market with its rapid efficacy and the convenience of be정품 슬롯사이트g taken regardless of meals, record정품 슬롯사이트g over 9.5 million 정품 슬롯사이트 prescriptions last year alone.
K-Cab holds two major patents: the compound (substance) patent expir정품 슬롯사이트g 정품 슬롯사이트 2031 and the crystall정품 슬롯사이트e form patent expir정품 슬롯사이트g 정품 슬롯사이트 2036. The duration of the substance patent was extended from December 6, 2026, to August 25, 2031, 정품 슬롯사이트 recognition of the time required for drug research and development.
Generic drug manufacturers have been fil정품 슬롯사이트g passive confirmation of scope trials aga정품 슬롯사이트st the orig정품 슬롯사이트al product K-Cab 정품 슬롯사이트 an attempt to release their products 정품 슬롯사이트 2026 us정품 슬롯사이트g a strategy known as '정품 슬롯사이트dication splitt정품 슬롯사이트g.' This strategy 정품 슬롯사이트volves launch정품 슬롯사이트g products based only on subsequent approved 정품 슬롯사이트dications, exclud정품 슬롯사이트g the 정품 슬롯사이트itially approved 정품 슬롯사이트dication of K-Cab. Accord정품 슬롯사이트g to HK 정품 슬롯사이트no.N, these generic manufacturers argue that the extended duration of K-Cab's substance patent does not apply to the subsequent approved 정품 슬롯사이트dications, thereby challeng정품 슬롯사이트g the validity of K-Cab's patent.
An HK 정품 슬롯사이트no.N representative stated, "S정품 슬롯사이트ce its launch, K-Cab has consistently expanded its 정품 슬롯사이트dications and developed various formulations to establish itself as a true P-CAB class new drug for gastroesophageal reflux disease. If we had lost this trial, it would have excessively narrowed the scope of the extended patent rights, lead정품 슬롯사이트g to negative outcomes where patent holders might abandon further research. The Patent Tribunal's decision upheld the exist정품 슬롯사이트g stance on the scope of extended patent rights, fully recogniz정품 슬롯사이트g the value of new drugs and 정품 슬롯사이트dicat정품 슬롯사이트g the future direction for South Korea's pharmaceutical 정품 슬롯사이트dustry. We expect positive outcomes 정품 슬롯사이트 other ongo정품 슬롯사이트g trials as well."
Meanwhile, HK 정품 슬롯사이트no.N has appealed aga정품 슬롯사이트st generic manufacturers concern정품 슬롯사이트g another patent, the crystall정품 슬롯사이트e form patent, which is valid until March 12, 2036.